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Abstract
Tau dysfunction characterizes neurodegenerative diseases such as Alzheimer’s disease (AD) and frontotemporal lobar
degeneration (FTLD). Here, we performed an unbiased SAGE (serial analysis of gene expression) of differentially expressed
mRNAs in the amygdala of transgenic pR5 mice that express human tau carrying the P301L mutation previously identified in
familial cases of FTLD. SAGE identified 29 deregulated transcripts including Sfpq that encodes a nuclear factor implicated in
the splicing and regulation of gene expression. To assess the relevance for human disease we analyzed brains from AD,
Pick’s disease (PiD, a form of FTLD), and control cases. Strikingly, in AD and PiD, both dementias with a tau pathology,
affected brain areas showed a virtually complete nuclear depletion of SFPQ in both neurons and astrocytes, along with
cytoplasmic accumulation. Accordingly, neurons harboring either AD tangles or Pick bodies were also depleted of SFPQ.
Immunoblot analysis of human entorhinal cortex samples revealed reduced SFPQ levels with advanced Braak stages
suggesting that the SFPQ pathology may progress together with the tau pathology in AD. To determine a causal role for
tau, we stably expressed both wild-type and P301L human tau in human SH-SY5Y neuroblastoma cells, an established cell
culture model of tau pathology. The cells were differentiated by two independent methods, mitomycin C-mediated cell
cycle arrest or neuronal differentiation with retinoic acid. Confocal microscopy revealed that SFPQ was confined to nuclei in
non-transfected wild-type cells, whereas in wild-type and P301L tau over-expressing cells, irrespective of the differentiation
method, it formed aggregates in the cytoplasm, suggesting that pathogenic tau drives SFPQ pathology in post-mitotic cells.
Our findings add SFPQ to a growing list of transcription factors with an altered nucleo-cytoplasmic distribution under
neurodegenerative conditions.
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Introduction
Alzheimer’s disease (AD) is characterized by both amyloid-b
(Ab) plaques and tau tangles in the brain while tau pathology in
the absence of plaques occurs in a subset of frontotemporal lobar
degeneration (FTLD-Tau) that includes FTDP-17 and Pick’s
disease (PiD) [1]. Features of FTLD-Tau have been reproduced in
transgenic mice expressing FTDP-17 mutant tau [2]: P301L tau
transgenic pR5 mice are characterized by tau hyperphosphoryla-
tion, tangle formation in the amygdala and hippocampus, and
memory impairment [3].
To determine the consequences of tau pathology, both in
animal models and human disease, we and others have applied the
tools of functional genomics [4]. Proteomic analysis, e.g., revealed
separate and synergistic modes of Ab and tau on mitochondrial
functions [5,6] while in a transcriptomic study, we identified the
detoxifying enzyme glyoxalase I as a target of tau toxicity [7].
These studies were all done with total brain, while here we focused
on the amygdala, a brain area with prominent tau pathology and
affected early on in AD pathogenesis. Furthermore, instead of
using gene arrays to identify differential gene expression, we used
the unbiased, though less frequently applied SAGE (Serial Analysis
of Gene Expression) method [8].
We identified 29 differentially expressed genes in pR5
transgenic amygdala, of which 11 were up- and 18 down-
regulated compared to non-transgenic controls. Among these was
Sfpq that encodes a nuclear splicing factor and transcriptional
regulator. Our subsequent analysis for the first time revealed a
nucleo-cytoplasmic redistribution of SFPQ under pathological
conditions, similar to what has been reported for TDP-43 that
forms cytoplasmic aggregates in amytrophic lateral sclerosis (ALS)
and FTLD-TDP [9], and FUS in ALS [10,11] and FTLD-FUS
[12]. This highlights the nucleo-cytoplasmic redistribution of
transcription factors as a prominent pathomechanism in neuro-
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35678degeneration. Our data suggest that pathological tau may cause
neuronal dysfunction, at least in part, by mislocalizing proteins
such as those implicated in mRNA processing and/or splicing.
Results
SAGE analysis of P301L tau-expressing mice
In P301L mutant tau transgenic pR5 mice, NFT formation is
initiated in the amygdala [13,14]. To determine differentially
regulated genes in pR5 mice compared to non-transgenic control
littermates, we isolated mRNAs from dissected amygdalae and
performed an unbiased SAGE analysis. We obtained 92,000
sequenced tags (46,586/wild-type and 46,905/pR5), which
allowed us to identify differentially expressed genes (Table 1).
By disregarding repetitive elements and SAGE linkers, most of the
mitochondrial genes in the library showed a reduced expression in
the transgenic sample. This included both mitochondrial and
nuclear encoded mitochondrial genes. Specifically, subunits 6 and
8 of ATP synthase F0 (mt-Atp6 and mt-Atp8) as well as subunit 3 of
Cytochrome c oxidase (mt-Co3) were down-regulated, while
subunit 1 of Cytochrome c oxidase (mt-Co1) was up-regulated.
These genes are encoded by the mitochondrial genome. The
nuclear encoded mitochondrial genes included isoforms 1 and 3 of
the ATP synthase subunit c (Atp5g1 and Atp5g3, respectively).
While in the wild-type sample, isoform 1 yielded 7 tags, in pR5 it
yielded none; isoform 1 yielded 42 tags in wild-type and only 17 in
pR5. This deregulation may contribute to the reduced mitochon-
drial activity that characterizes pR5 mice as shown by us
previously, both at the level of the proteome and functionally
[5,15]. In addition to mitochondrial genes, 24 genes were
identified that reached a significance of p,0.01 of differential
regulation (Table 1). Of these, 9 were up- and 14 down-regulated.
They included genes with functions in mitochondrial/homeostasis,
transcription/gene expression, transport, cell growth/division,
signaling pathways, and others (Fig. 1A).
Deregulated genes
We identified a total of 29 genes that were significantly
deregulated in pR5 amygdala (Table 1). Importantly, several of
these have been implicated in neurodegenerative diseases other
than AD or FTD, in particular those with functions in
mitochondria. For example, among the up-regulated genes in
pR5 amygdala is Itm2c that encodes an integral membrane
protein. Genetic variants of ITMC2 have been associated with
hemorrhagic stroke in humans [16]. Ttr encoding transthyretin is
also up-regulated; gene mutations have been implicated in
multiple forms of amyloid polyneuropathy, a disease characterized
by systemic deposition of TTR amyloid [17,18]. Enpp2 is up-
regulated; it encodes a phosphodiesterase also known by the name
of autotaxin, that has a possible role in metastasis [19].
Cplx2 is among the down-regulated genes in pR5 amygdala. It
encodes complexin 2, an essential protein with a role in synaptic
vesicle fusion [20]. Abnormal levels of CPLX2 have been
implicated in Huntington’s disease [21], while its levels are
reduced in AD [22]. Septin 3 and 5 are both down-regulated in
pR5, with Septin 5 accumulating in Parkinson’s disease (PD) brain
[23]. Septins play important roles in many cellular processes by
providing rigidity to the cell membrane, serving as scaffolds to
recruit proteins to specific subcellular loci, and creating membrane
diffusion barriers to establish discrete cellular domains [24].
Another down-regulated gene is Pja1 that encodes the E3 ubiquitin
ligase Praja that is expressed abundantly in brain and that has
been proposed as a candidate gene in X-linked mental retardation
(MRX) [25]. Pja1 is up-regulated in the basolateral amygdala
during the formation of fear condition memory [26], and
interestingly, it is in the basolateral amygdala where pR5 mice
specifically accumulate tau [27]. Finally, Dbn1 is down-regulated
in the pR5 amygdala. This gene encodes the actin-binding
postsynaptic protein drebrin1 that regulates synaptic plasticity. Its
levels are reduced in hippocampal synapses in AD [28], and its
mRNA levels were found to negatively correlate with PHF-tau, i.e.
abnormally phosphorylated tau [29].
Deregulation of the gene encoding SFPQ
While several genes were identified as being deregulated based
on just one tag, for others, up to four tags were represented in the
SAGE library, increasing the confidence in the finding of
deregulation (Table 2). The latter group included Sfpq (splicing
factor proline/glutamine rich) that encodes a large nuclear
protein, SFPQ, implicated in cellular processes such as transcrip-
tional regulation and RNA splicing. The protein is also known as
PSF (Polypyrimidine tract-binding protein-associated Splicing
Factor) [30–32]. The 707 amino acid-long nuclear protein SFPQ
is highly conserved and contains an amino-terminal glutamic
Figure 1. Deregulation of the nuclear factor Sfpq in tau transgenic mice. (A) Transcriptomic SAGE analysis of P301L tau mutant pR5 (TG)
compared to wild-type (WT) amygdala identified differentially expressed genes within several functional categories (pie chart). The strongly
deregulated ‘transcription’ genes (green) included Sfpq. (B) Scheme of the domain structure of the 707 amino acid-long nuclear protein SFPQ. The
amino-terminal glutamic acid (E)/glutamine(Q)/proline(P)-rich domain is followed by two RNA/DNA-binding domains (RRMs).
doi:10.1371/journal.pone.0035678.g001
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RNA/DNA-binding domains (RRMs) (Fig. 1B). SFPQ is
expressed by neurons and glia, and in both it is confined to nuclei
(Fig. 2).
Nuclear depletion of SFPQ in AD and PiD brain
We next analyzed SFPQ in human diseases with tau pathology,
by staining paraffin-embedded sections from the hippocampal
formation of six sporadic AD cases, six sporadic PiD cases, and
eight non-demented CT controls. SFPQ was completely depleted
from most nuclei in AD and PiD hippocampi, and accumulated in
focal patches in the cytoplasm, resembling aggregates (Fig. 3A).
Interestingly, double immunofluorescence (IF) for SFPQ/GFAP or
SFPQ/MAP2 revealed that in both AD and PiD brain, SFPQ was
depleted from nuclei in both neurons and astrocytes (Fig. 3B).
Accordingly, neurons harboring either AD tangles or PiD Pick
bodies were also depleted of SFPQ as shown by co-staining for
phospho-tau (AT8), SFPQ and DAPI (Fig. 3C). Immunoblot
analysis of human entorhinal cortex samples with Braak stage 0
(CT), entorhinal stages I–II (minimal AD pathology) and
neocortical stages V–VI (terminal pathology) revealed
65.366.7% reduced SFPQ levels for stages I–II, and a
78.761.9% reduction for V–VI compared with CT (Fig. 3D).
This suggests that the SFPQ pathology may progress together with
the tau pathology in AD.
Tau induces cytoplasmic sequestration of SFPQ
To determine the effects of pathological tau on SFPQ directly,
we stably expressed both wild-type and P301L human tau in
human SH-SY5Y neuroblastoma cells, a cell culture model of tau
pathology [33], followed by either mitomycin C (Mito C)-
mediated cell cycle arrest or neuronal differentiation with retinoic
acid (RA). Confocal microscopy revealed that SFPQ was confined
to nuclei in non-transfected wild-type cells, whereas in both wild-
Table 1. SAGE (Serial Analysis of Gene Expression) analysis in the amygdala of P301L tau mutant pR5 mice identifies 29
deregulated genes that includes Sfpq.
# Gene name Tag WT P301L P value Unigene
1 Sfpq, Splicing factor proline/glutamine rich combined 0.0 8.0 0.0041 Mm.277094
2 Zranb1, Zinc finger, RAN-binding domain 1 AGGAGATGGAG 0.0 7.0 0.0079 Mm.389984
3 XAP5 protein TTGGAGCTGGA 0.0 7.0 0.0079 Mm.4370
4 Enpp2, ectonucleotide pyrophosphodiesterase 2 combined 4.0 16.0 0.0076 Mm.250256
5 Sh3glb2, SH3-domain GRB2-like endophilin B2 combined 6.0 22.9 0.0015 Mm.33343
6 Gfra4, Glial cell line derived neurotrophic factor family receptor alpha 4 TGCACTGAGAA 5.0 17.9 0.0069 Mm.198399
7 Ttr, transthyretin combined 20.1 49.8 0.0003 Mm.2108
8 Kcnk1, Potassium channel, subfamily K, member 1 GCAGATGGCAA 18.1 37.9 0.0081 Mm.10800
9 Ppp3cb, Protein phosphatase 3, catalytic subunit, beta isoform combined 66.2 110.6 0.0008 Mm.274432
10 Itm2c, integral membrane protein 2C GTAGTGGAGCC 75.3 119.6 0.0015 Mm.29870
11 mt-Co1, Cytochrome c oxidase subunit I GCTGCCCTCCC 1.0 12.0 0.0019 NA
12 mt-Co3, Cytochrome c oxidase, subunit III ATACTGACATT 442.5 332.9 0.0001 NA
13 mt-Atp8, ATP synthase, F0 subunit 8 ATAATACATAA 868.0 652.8 3E-08 NA
14 Atp5g1, ATP synthase, F0 complex, isoform 1 CCAGTCCTGGT 42.1 16.9 0.0010 Mm.371547
15 Atp5g3, ATP synthase, F0 complex, isoform 3 GCAAACAAGAT 7.0 0.0 0.0076 Mm.2966
16 Sepw1, selenoprotein W, muscle 1 TTTCCAGGTGT 99.3 62.8 0.0041 Mm.42829
17 Cplx2, Complexin-2 ATGACAAAGAA 59.2 31.9 0.0042 Mm.268902
18 Gtf2ird1, General transcription factor II repeat domain-containing 1 TAAGTGGAATA 26.1 10.0 0.0072 Mm.332735
19 Sept3, Septin 3 combined 41.1 19.9 0.0066 Mm.309707
20 Sept5, Septin 5 CTCCGTTTTGT 47.2 16.9 0.0001 Mm.20365
21 Mtpn, Myotrophin TACATCCGAAT 18.1 5.0 0.0063 Mm.182746
22 Dbn1, Drebrin 1 GCAATAAATGG 29.1 8.0 0.0004 Mm.19016
23 Papola, poly (A) polymerase alpha ACTGGAGTTTG 10.0 1.0 0.0062 Mm.255877
24 Pja1, praja1, RING-H2 motif containing combined 10.0 1.0 0.0062 Mm.8211
25 Rpo1-4, RNA polymerase 1–4 GCTGGAACTGG 7.0 0.0 0.0076 Mm.135581
26 1700021K19Rik, RIKEN cDNA 1700021K19 gene GTCATCTTTAA 7.0 0.0 0.0076 Mm.327319
27 H2afv, H2A histone family, member V TGTTGATTGGC 7.0 0.0 0.0076 Mm.27624
28 Tmed8, Transmembrane emp24 domain containing 8 combined 7.0 0.0 0.0076 Mm.374912
29 Clk1, CDC-like kinase 1 GCCAAACCAAA 13.87 3.03 0.0085 Mm.1761
SAGE was used to obtain a total of 92,000 sequence tags from pooled amygdalae dissected from ten 10 month-old male pR5 mice (P301L) and ten wild-type (WT)
littermate controls. Numbers of counted tags are listed for the two genotypes; ‘combined’ indicates that more than one tag was obtained per deregulated gene (for
these, the individual tags are listed in Table 2). 29 genes presented a significant (p,0.01) regulation, including nuclear and mitochondrial encoded mitochondrial genes
that are shown in light grey (Gene ID for mt-Co1: 17708; mt-Co3: 17710; mt-Atp8: 17706). Of these, 11 were up- (in white) and 14 down-regulated (in grey), with
mitochondrial genes indicated (in bold).
doi:10.1371/journal.pone.0035678.t001
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tiation method, it formed vesicular aggregates in the cytoplasm
(Fig. 4A). These were more pronounced in the mutant, and were
remarkably similar to those identified in P301L tau-expressing
cells. Within the sensitivity of the Western blot assay, total levels of
SFPQ were not altered under any of these conditions (Fig. 4B).
Together this suggests that pathogenic tau drives SFPQ pathology
in post-mitotic cells. How tau causes the altered nucleo-
cytoplasmic distribution of SFPQ remains to be determined.
Discussion
By using SAGE as an unbiased transcriptomic approach we
identified Sfpq as a downstream target of tau. We further found a
nucleo-cytoplasmic redistribution of the nuclear protein SFPQ in
AD and PiD pointing at a putative role for deregulated
transcription factors in neurodegeneration. For both TDP-43
and FUS, a similar redistribution has been reported in ALS, and
FTLD-TDP or FTD-FUS, respectively [9,12]. SFPQ promotes
neuronal survival in development [34], and increased SFPQ levels
sensitize neurons to excitotoxic damage in vitro [35]. Hence,
although tau itself may have nuclear functions [36], the nuclear
depletion of SFPQ identified here suggests that pathological tau
may cause neuronal dysfunction, at least in part, by mislocalizing
proteins with nuclear functions. This extends the molecular targets
of pathological tau beyond axons and dendritic processes [37,38].
SFPQ is a transcriptional repressor of several genes, by inhibiting
transcriptional co-activators or by binding to a consensus
palindromic sequence (CTGAGTC) in the promoter region
[39,40]. Two of these sequences are found in the putative Sfpq
promoter suggesting that SFPQ may repress its own transcription.
SFPQ not only functions as a repressor of gene transcription, but it
can also up-regulate gene expression by increasing mRNA stability
as shown for the inducible Cyclooxygenase-2 (Cox-2) gene [41].
Arresting P301L tau-expressing SH-SY5Y cells with either
mitomycin C (mito C) or retinoic acid (RA), which causes a
cytoplasmic accumulation of SFPQin P301L tau-expressing cells and
not, untransfected controls, rules out a direct role for mitosis in the
altered localization of SFPQ. In addition, neurons are post-mitotic so
the cytoplasmic localization found by us for SFPQ in AD and PiD
brains cannot be due to mitosis. SFPQ redistribution could eventually
induce cell death by contributing to apoptosis or mitosis, since a
Figure 2. Neuronal and glial expression of SFPQ revealed in
non-transgenic wild-type (CT) control mouse brain shown for
the amygdala (A) and the hippocampus (B,C). Double immuno-
fluorescence for SFPQ (green)/MAP2 (red) (A,B) and SFPQ (green)/GFAP
(red) (C) reveals an exclusively nuclear localization in both neurons and
astrocytes of WT mice.
doi:10.1371/journal.pone.0035678.g002
Table 2. List of SAGE tags of deregulated genes for which
multiple tags were identified.
Gene name Tag WT P301L Ratio P value UniGene
Sfpq combined 0 8,0 15,9 0,0041 Mm.277094
TTGTGTGCTGT 0 3,0 6,0 0,1259
GGTCAGCTAAA 0 2,0 4,0 0,2512
CGTACTGAGCG 0 2,0 4,0 0,2512
ATCCACAGTCC 0 1,0 2,0 0,5012
Enpp2 combined 4,0 16,0 4,0 0,0076 Mm.250256
GTGCTGCCAGT 3,0 12,0 4,0 0,0219
AAGATGCACAC 1,0 4,0 4,0 0,2239
Sh3glb2 combined 6,0 22,9 3,8 0,0015 Mm.295493
GCTCTGGCTGG 6,0 20,9 3,5 0,0039
GATCCCGACTG 0 2,0 4,0 0,2512
Ttr combined 20,1 49,8 2,5 0,0003 Mm.2108
TTCAAAAGCCC 2,0 2,0 21,0 1
GAACGGGGAAA 1,0 10,0 9,9 0,0066
AATTCGCGGAT 17,1 37,9 2,2 0,0049
Ppp3cb combined 66,2 110,6 1,7 0,0008 Mm.24381
TGCAAAGCTCC 1,0 1,0 21,0 1
GGCCGCTGCTC 62,2 105,6 1,7 0,0008
GGCCGCTGCAA 3,0 4,0 1,3 0,7413
Sept3 combined 41,1 19,9 22,1 0,0066 Mm.309707
TAGATGTTGCT 36,1 17,9 22,0 0,0135
TACATTTTGCT 1,0 1,0 21,0 1
GTGTACATACA 4,0 1,0 24,0 0,2138
Pja1 combined 10,0 1,0 210,1 0,0062 Mm.8211
TTCCCTCCCCC 1,0 0 22,0 0,5012
GGTTAATGTTC 9,0 1,0 29,1 0,0115
Tmed8 combined 7,0 0 214,1 0,0076 Mm.374912
GGCTAAAATAA 6,0 0 212,1 0,0151
ACCAGCTCTCA 1,0 0 22,0 0,5012
Significance was reached by combining the counts of multiple tags for the
same gene.
doi:10.1371/journal.pone.0035678.t002
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apoptotic cells, and a cytoplasmic redistribution in mitotic cells
[42,43]. It is therefore possible that stressed neurons try to cope with
elevated tau levels by cytoplasmic sequestration of SFPQ.
Loss of nuclear SFPQ and/or its cytoplasmic accumulation may
contribute to cellular degeneration also directly: The Sfpq
homologue whitesnake is required for cell survival and normal brain
development in zebrafish, where it is mostly detected in regions
enriched with neuronal precursors: this suggests that an impairment
in SFPQ function could contribute to neuronal cell death [34]. Sfpq
overexpression per se may contribute to neuronal death since SFPQ
sensitizes neurons to neurotransmitter-induced death in vitro [35].
Furthermore, studies in a cancer cell line identified SFPQ as a
tumor suppressor suggesting that an altered distribution and
depletion from nuclei could affect transcription of target genes [44].
Together, our finding of an aberrant cytoplasmic localisation of
SFPQ in both AD and PiD brains and P301L tau-expressing SH-
SY5Y neuroblastoma cells suggests a role for SFPQ in neurode-
generation with a tau pathology. Our study further links FTLD-
Tau with the cytoplasmic aggregation of the nuclear protein SFPQ
to FTLD-TDP with the cytoplasmic aggregation of the nuclear




Human brain tissue was obtained from the Australian Brain
Bank Network’s Sydney Brain Bank, with approval from the
Human Ethics Review Committee of the University of Sydney.
Written informed consent was obtained from donors or donors
next of kin for brain donation. The animal experiments were
approved by the Animal Ethics Committee (AEC) of the
University of Sydney and the Animal Care Committee of the
University of Cologne (approval number K00/1-2009/3/
4914).
Transgenic mice
The pR5 mouse strain expresses the longest human tau isoform
together with the FTLD-Tau (FTDP-17) pathogenic mutation
P301L in neurons, with NFT formation occurring first in the
amygdala and then in the hippocampus [13,27,48].
RNA isolation
For the SAGE analysis, amygdalae were dissected from ten 10
month-old male pR5 mice and ten wild-type male littermate
controls. At 5–6 months of age, NFT formation is initiated in the
amygdala, with numbers increasing as the mice age. Phenotyp-
ically the mice show no obvious impairment, neither at 5 nor at
10 months of age [13,14]. Brains were homogenized in Trizol
(Invitrogen, Carlsbad, CA) to isolate high quality RNA, following
the manufacturer’s instructions. To remove contaminating DNA,
the RNA was incubated with RNase-free DNase I (Promega,
Wisconsin, MD) and quantified by UV spectroscopy at 260 nm.
Between 10 and 30 mg of RNA was obtained from each
amygdala, and RNA integrity was confirmed by gel electropho-
resis using Bioanalyser chromatography (Agilent, Santa Clara,
CA).
Figure 3. Nucleo-cytoplasmic redistribution of SFPQ in human disease. (A) Compared to controls (CT), SFPQ (green) is massively depleted
from hippocampal nuclei in AD and PiD cases. It accumulates in patches (arrows) in the cytoplasm as shown by co-staining with nuclear DAPI (blue)
at higher magnification (insets). (B) IF for SFPQ (green) and GFAP or MAP2 (red) reveals that in both AD and PiD brain, SFPQ is almost completely
depleted from neuronal and astrocytic nuclei. (C) Neurons harboring AD tangles and PiD Pick bodies are similarly depleted of SFPQ (green) as shown
by co-staining for phospho-tau (AT8, red) and DAPI (blue). (D) Immunoblot analysis of Braak stage 0 (CT), entorhinal stage I–II of AD pathology, and
neocortical stage V–VI (terminal pathology) reveals massively reduced SFPQ levels as disease progresses (n=6–8; *,p,0.01; **,p,0.001). Scale bars,
10 mm.
doi:10.1371/journal.pone.0035678.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35678Figure 4. Tau transfection causes SFPQ aggregation in postmitotic cells. (A) Mitomycin C (Mito C)-mediated cell cycle arrest or neuronal
differentiation with retinoic acid (RA) of V5-tagged wild-type or P301L tau-expressing SH-SY5Y compared to untransfected (CT) SH-SY5Y
neuroblastoma cells reveals SFPQ aggregates (arrows) in the cytoplasm that are not seen in CT. Insets: detailed view of vesicular SFPQ in the
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SAGE libraries were established by Memorec Stoffel GmbH
(Cologne, Germany) as described [49], using 20 mg of total RNA
pooled from the two genotypes. Enrichment of mRNA was
achieved by affinity chromatography, using oligo-dT-coupled
Dynabeads (Dynal, Invitrogen, Carlsbad, CA). In brief, mRNA
was converted to cDNA using oligo-d(T)25 primers (Invitrogen)
and Superscript II reverse transcriptase (Gibco BRL, Carlsbad,
CA). The single-stranded cDNA was converted to double-stranded
cDNA and digested with Nla III as the anchoring enzyme. After
ligation of linkers to the Nla III-compatible sticky ends, the cDNA
fragments were digested with the tagging enzyme BsmF I (a site
present in the linkers) for 1 h at 65uC, thus generating 10 bp (base
pairs) SAGE cDNA tags attached to the linkers. After blunting of
the linker cDNA products with Klenow enzyme, dimerization and
PCR amplification using primers directed against linker sequences,
the linkers were excised by Nla III digestion. The released ditag
was purified from the excised linkers by polyacrylamide gel
electrophoresis (PAGE) and ligated to long multimers of ditags
separated by Nla III sites. After size separation by PAGE, the 0.7-
to 2-kb fraction was excised from the gel, purified, and cloned into
the pZero-1.1 vector (Invitrogen). Competent TOP10 E. coli
(Invitrogen) were transformed, and colonies screened by PCR for
inserts using M13F and M13R primers. Positive clones were
sequenced until 46,000 tags/genotype were obtained. SAGE data
were analyzed using the SAGE
TM software (Memorec Stoffel
GmbH, Cologne, Germany), an extensive proprietary tag
database that establishes automatic annotations derived from
EST/genomic data and, in addition, contains 700 manually
annotated tags elusive to the automated mapping. The program
extracts 11 bp SAGE tags and guarantees a more reliable
assignment to UniGene clusters than programs working with
10 bp tags. Proprietary filtering algorithms eliminate SAGE
artifacts resulting from polymorphic tags, ribosomal RNA, linker
tags and LINE/SINE tags. For comparison, all SAGE libraries
were normalized to 100,000 tags. The calculation of statistical
significance levels in SAGE is based on a formula developed by
Audic and Claverie [50]. Significance was ascribed for p,0.01.
Human brain samples
Human brains were collected within 80 hours of death and
frozen at 280uC for biochemical analysis or paraffin-embedded
for immunofluorescence (IF) staining. For histology tissue from six
sporadic AD (age range 63–78, mean 69.766.0), six sporadic PiD
(age range 62–78, mean 69.866.3) and eight control (CT) cases
(age range 62–79, mean 70.866.3) was used. Frozen entorhinal
cortex from six sporadic AD cases at neocortical Braak stages V–
VI (age range 76–98, mean 86.369.0), six clinically silent cases,
histologically at transentorhinal Braak stages I–II (age range 92–
103, mean 99.065.4) and six control cases without tangles (age
range 79–93, mean 85.766) was used for biochemical analysis.
Controls were free from psychiatric, neurological or neuropath-
ological diseases. None of the AD or PiD cases had a family history
suggestive of an autosomal dominant disease.
Antibodies
The following antibodies were used: a rabbit polyclonal
antibody (Abcam #ab38148; WB (immunoblotting) 1/1000; IF
(immunofluorescence) 1/200) was used to detect SFPQ. Mouse
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Ab-
cam, Cambridge, MA) and a mouse anti-a-actin antibody were
used as loading control (Chemicon, North Ryde, NSW, Australia).
Tau13 was used to detect human tau (Abcam; #ab24634; IF 1/
1000), a mouse monoclonal antibody against GFAP to stain
astrocytes (Sigma, St Louis, MO; #G3893; IF 1/1000), a mouse
monoclonal MAP2 antibody to stain neurons (Sigma; #M4403; IF
1/500), and mouse monoclonal antibody to detect the V5 tag
(Invitrogen, IF 1/400). Secondary antibodies were coupled to
Alexa-488 (Molecular Probes, USA, red, 1/200) or 2555 (green,
1/200) for confocal microscopy. DAPI (49,6-diamidino-2-pheny-
lindole, dihydrochloride) (Molecular Probes, Invitrogen) was used
for nuclear staining.
Immunofluorescence and Western blot analysis
Immunofluorescence and Western blot analysis of murine and
human tissue were done as described previously [51].
Cell lines and immunofluorescence staining
SH-SY5Y is human neuroblastoma cell line [52]. P301L-
expressing SH-SY5Y cells and mock controls were generated using
lentiviral gene transfer [53]. The cells were grown in DMEM
(Invitrogen) containing 10% of heat inactivated fetal bovine serum
(FBS) and penicillin/streptomycin (Invitrogen) with or without
blasticidin (Invitrogen) [51]. Growth arrest was achieved by
incubating cells for 2 h with 10 mg/ml mitomycin C (mito C)
followed by a 24 h recovery, and neuronal differentiation by
incubation with 20 mM all-trans-retinoic acid for 24 h, respec-
tively. For immunofluorescence staining, cells were plated at a
density of 20.000 cells per cm
2 on 13 mm plastic cover slips
(Sarstedt, Ingle Farm, SA, Australia), followed by fixation in 4%
PFA. Blocking and permeabilization was done in 10% BSA and
0.3% Triton X-100 in 0.1 M PBS for 1 h. Primary antibodies
were incubated overnight at 4uC in 5% BSA, 0.1 M PBS.
Secondary antibodies were coupled to Alexa-488 or -555
(Molecular Probes, USA), followed by confocal microscopy.
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